Results 151 to 160 of about 19,491 (256)

Regiodivergent C3 and C4 Amination of Quinolines via Radical and Ionic Pathways

open access: yesAngewandte Chemie, Volume 138, Issue 16, 13 April 2026.
A regiodivergent strategy converts a single N‐aminoquinolinium precursor into either C3‐ or C4‐aminated quinolines. Nucleophile‐induced dearomatization diverges into light‐driven N‐centered radical capture (C3) or base‐promoted SNAr (C4), enabling rapid assembly of aminoquinoline libraries and late‐stage diversification.
Ye‐Eun Kim   +3 more
wiley   +2 more sources

Gaining insights into MmpL3: combining structural and computational approaches to unlock transport and inhibitor‐binding mechanisms

open access: yesActa Crystallographica Section D, Volume 82, Issue 5, Page 550-570, May 2026.
This study investigates the mycobacterial membrane protein MmpL3, a key target for new antituberculosis drugs, by combining high‐resolution crystallography and computational simulations. It reveals how the inhibitor UPAR‐1109 binds to MmpL3, providing detailed insights into the function and flexibility of the protein and supporting the rational design ...
Satoshi Murakami   +9 more
wiley   +1 more source

Deciphering the biosynthetic pathways of lichen acids

open access: yesNew Phytologist, Volume 250, Issue 3, Page 1784-1799, May 2026.
Summary Depsides and depsidones are polyketide‐derived lichen acids widely distributed in lichen thalli, yet the biosynthetic gene clusters (BGCs) responsible for their production remain poorly understood. To address this gap, we investigated the diversity and evolutionary relationships of polyketide BGCs in lichens.
Wonyong Kim   +11 more
wiley   +1 more source

Discovery of [1,2,4]triazolo[1,5‐a]pyrimidine‐Imatinib Hybrids With Selective Cytotoxic Activity: A Mechanistically Divergent Series From Direct BCR‐ABL1 Inhibition

open access: yesChemMedChem, Volume 21, Issue 8, 28 April 2026.
Discovery of imatinib–triazolopyrimidine hybrids with selective cytotoxicity and a mechanism distinct from classical BCR‐ABL1 inhibition. This bioisosteric strategy introduces a novel compounds, paving the way for innovative antileukemic therapies with differentiated profiles.
Stefany Castro Bazan Moura   +10 more
wiley   +1 more source

Association of mating-type with mycelium growth rate and genetic variability of Fusarium culmorum

open access: yesOpen Life Sciences, 2013
Irzykowska Lidia   +2 more
doaj   +1 more source

Structure‐ and Ligand‐Based Discovery of Novel 3‐Chymotrypsin‐Like Protease Nonpeptidomimetic Hits

open access: yesChemMedChem, Volume 21, Issue 7, 14 April 2026.
A multistep virtual screening cascade, integrating shape‐based, ensemble docking, and quantitative structure–activity relationship (QSAR) models, was employed to screen 1.5 million compounds. This funnel identified a novel 3‐chymotrypsin‐like protease (3CLpro) inhibitor, LabMol‐499, which was experimentally validated using a Förster Resonance Energy ...
Sabrina Silva‐Mendonça   +14 more
wiley   +1 more source

Molecular LEGION: incalculably large coverage of chemical space around the NLRP3 target. [PDF]

open access: yesSci Data
Zagribelnyy B   +11 more
europepmc   +1 more source

Yersinia enterocolitica O:3 Outer Membrane Vesicles as a Platform for Complement Activation. [PDF]

open access: yesJ Extracell Vesicles
Battaglino C   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy